CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

  • With its highly scalable Adenovirus and AAV production technologies, CEVEC provides cutting-edge manufacturing solutions for two of the most widely used gene therapy vectors
  • Funding will expand cell line development capacities for ELEVECTA® stable AAV
    producer cell lines
  • With ELEVECTA® currently being implemented in a second host cell type, an even stronger demand is expected

Cologne, Germany, July 27, 2021

CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies

  • CARISMA receives full rights to use the CAP® Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications
  • CEVEC’s unique CAP® cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors
  • The agreement supports CARISMA’s development of novel CAR-macrophage immunotherapies, a first-of-its-kind approach to the treatment of solid tumors

Cologne, Germany and Philadelphia, PA, February 2, 2021

CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA® in gene therapy

  • Under the agreement CEVEC grants Biogen rights to its proprietary ELEVECTA® Technology for manufacturing of gene therapy products
  • ELEVECTA® stable producer cell lines enable fully scalable, helper virus-free AAV vector production in suspension bioreactors

Cologne, Germany, January 8, 2021

CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA® Technology in gene therapy

  • Agreement will allow Roche to use CEVEC’s unique and proprietary ELEVECTA® Technology for AAV vector manufacturing
  • The ELEVECTA® Stable Producer Cell Lines are designed to enable fully scalable, high-performance biopharmaceutical industry

Cologne, Germany, November 10, 2020

CEVEC and Rznomics sign license agreement for the use of CAP® Technology in manufacturing of adenoviral vectors

  • Rznomics will use the technology for gene therapies based on their proprietary trans-splicing ribozyme technology targeting various cancer indications
  • CEVEC’s unique CAP® cell line enables by design the efficient production of high-quality adenoviral vectors

Cologne, Germany and Yongin, Korea, October 19, 2020

CEVEC Announces the Launch of the ELEVECTA® Platform – the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors

  • ELEVECTA® takes viral vector manufacturing to the next level to serve the rapidly growing market of gene therapy applications
  • Growing serum-free in suspension, ELEVECTA® producer cell lines enable fully scalable high-performance AAV vector production based on standardized processes widely used in industry for monoclonal antibody production
  • With all components stably integrated into one cell, the ELEVECTA® technology provides large scale AAV production without expensive cGMP-grade plasmids and complex transient transfection steps

 Cologne, Germany, April 28, 2020

CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use

  • Agreement with Evox Therapeutics supports the utility of CAP® technology in the production of exosomes
  • Exosomes offer distinct advantages as highly effective drug carriers
  • Evox Therapeutics intends to develop CAP®-derived exosomes for several disease areas and indications

Cologne, Germany, April 16, 2020

© CEVEC Pharmaceuticals GmbH 2020